Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Co.'s pipeline includes product candidates that utilize its understanding of the tumor microenvironment, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to support critical components required for an anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents, and induction of an immune response via activators on effector cells in the tumor microenvironment. The CMPX stock yearly return is shown above.
The yearly return on the CMPX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CMPX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|